Medtronic launches DxTerity Diagnostic Angiography Catheter line for use in diagnostic cardiac catheterization procedures and percutaneous coronary intervention.

Medtronic plc has announced that its market-leading coronary portfolio will now include the DxTerity Diagnostic Angiography Catheter line and several transradial-specific products including the DxTerity TRA, InTRAkit access kit and TRAcelet compression device, all of which have received FDA clearance and CE (Conformit� Europ�enne) Mark for use in diagnostic cardiac catheterization procedures and percutaneous coronary intervention (PCI).

DxTerity products comprise a transradial diagnostic catheter and accompanying transradial devices to facilitate the treatment of coronary artery disease via the radial artery in the wrist.

In the United States, Medtronic also launched the Transradial Arc Curriculum, a fully-customizable education and training solution for physicians, staff and administrators to ensure successful adoption of the transradial approach from access to patent hemostasis. The curriculum aims to provide robust clinical training and enhance patient care pathways through a hospital-specific approach to help institutions optimize the delivery of transradial care.

A meta-analysis of randomized studies that studied the transradial approach generally have found that procedures via the transradial approach (through a patient's wrist) have been associated with cost savings, reduced mortality and improved safety with reductions in major bleeding and vascular complications.

Comment: The DxTerity and DxTerity TRA diagnostic catheters are used to determine if revascularisation is required in patients with coronary artery disease. Additionally the DxTerity TRA diagnostic catheters are specifically designed for transradial access and allow for engagement of both coronary arteries without catheter exchange.